CD274 and non-small cell lung carcinoma: A derivative study of KEYNOTE-001 demonstrated that advanced NSCLC patients with high PD-L1 expression (>= 50% of tumor cells) had better ORR than those with low PD-L1 (< 50% of tumor cells) expression who received pembrolizumab (75).